Source:http://linkedlifedata.com/resource/pubmed/id/18949681
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0012155,
umls-concept:C0017337,
umls-concept:C0028754,
umls-concept:C0086860,
umls-concept:C0332281,
umls-concept:C0389071,
umls-concept:C0599883,
umls-concept:C0681850,
umls-concept:C0948265,
umls-concept:C1274040,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C1882417,
umls-concept:C2349001,
umls-concept:C2697811
|
| pubmed:issue |
1
|
| pubmed:dateCreated |
2008-12-3
|
| pubmed:abstractText |
Adiponectin is an adipose tissue-specific hormone that is commonly decreased in obese subjects. Furthermore, single-nucleotide polymorphisms (SNPs) of the adiponectin gene have been associated with metabolic phenotypes. The present study investigated whether the adiponectin gene promoter variant -11391 G/A (rs17300539) could predict the risk of developing traits characterizing the metabolic syndrome (MetS) and the impact of weight management. The -11391 G/A SNP was genotyped in 180 Spanish volunteers (BMI: 31.4+/-3.2 kg/m (2); age: 35+/-5 years). Clinical measurements were determined at baseline, following an 8-week low-calorie diet (LCD), and at 32 and 60 weeks. At baseline, the GG genotype was associated with higher HOMA-IR, insulin and triacylglyceride concentrations than other genotypes (p<0.05) and was also related with a higher risk of insulin resistance (OR: 2.437, p=0.025) and MetS clinical manifestations (OR: 3.236, p=0.003). Following the LCD, the increased risk in GG subjects compared with others disappeared (p>0.05). By 32 weeks after dietary therapy (n=84), GG carriers had recovered the risk of metabolic comorbidities (OR: 2.420, p=0.043). This risk was even more evident after 60 weeks (OR: 2.875, p=0.014). These data show an increased risk of insulin resistance and MetS complications in obese subjects of the -11391 GG genotype. The risk was markedly reduced during an energy-restricted diet, but was not sustained. Carriage of the A allele therefore confers protection from weight regain, and the effect is particularly evident 32-60 weeks after the dietary intervention, when improvement in GG subjects had disappeared.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0018-5043
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
55-61
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:18949681-Adiponectin,
pubmed-meshheading:18949681-Adult,
pubmed-meshheading:18949681-Comorbidity,
pubmed-meshheading:18949681-Diet, Reducing,
pubmed-meshheading:18949681-Energy Intake,
pubmed-meshheading:18949681-Female,
pubmed-meshheading:18949681-Gene Frequency,
pubmed-meshheading:18949681-Genetic Linkage,
pubmed-meshheading:18949681-Genotype,
pubmed-meshheading:18949681-Humans,
pubmed-meshheading:18949681-Insulin Resistance,
pubmed-meshheading:18949681-Male,
pubmed-meshheading:18949681-Metabolic Syndrome X,
pubmed-meshheading:18949681-Middle Aged,
pubmed-meshheading:18949681-Obesity,
pubmed-meshheading:18949681-Polymorphism, Single Nucleotide,
pubmed-meshheading:18949681-Promoter Regions, Genetic,
pubmed-meshheading:18949681-Treatment Outcome,
pubmed-meshheading:18949681-Weight Loss
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
The - 11391 G/A polymorphism of the adiponectin gene promoter is associated with metabolic syndrome traits and the outcome of an energy-restricted diet in obese subjects.
|
| pubmed:affiliation |
Department of Nutrition and Food Sciences, Physiology and Toxicology, University of Navarra, Pamplona, Spain.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|